Company news

Nuvation Bio Inc. news in 2025

Nuvation Bio Inc.'s news releases, calls and decks from 2025, newest first.

View company

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

December 6, 2025

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

December 3, 2025

Nuvation Bio to Participate in Upcoming Investor Conferences

November 26, 2025

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

November 3, 2025

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 23, 2025

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

October 20, 2025

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

September 30, 2025

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

September 19, 2025

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

September 7, 2025

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 5, 2025

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 24, 2025

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

June 24, 2025

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

June 11, 2025

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 13, 2025

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Nuvation Bio to Present at The Citizens Life Sciences Conference

May 1, 2025

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

April 22, 2025

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

April 2, 2025

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

March 25, 2025

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 6, 2025

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

March 3, 2025

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

February 24, 2025

Calls in 2025

Decks in 2025